New Risk • 23h
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.2% per year over the past 5 years. Revenue is less than US$1m (LK₨315m revenue, or US$945k). Market cap is less than US$10m (LK₨1.98b market cap, or US$5.93m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). Reported Earnings • May 16
First quarter 2026 earnings released: EPS: LK₨0.17 (vs LK₨0.083 in 1Q 2025) First quarter 2026 results: EPS: LK₨0.17 (up from LK₨0.083 in 1Q 2025). Revenue: LK₨86.5m (up 29% from 1Q 2025). Net income: LK₨20.2m (up 115% from 1Q 2025). Profit margin: 23% (up from 14% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. New Risk • Nov 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Sri Lankan stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.6% per year over the past 5 years. High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m (LK₨277m revenue, or US$901k). Market cap is less than US$10m (LK₨1.97b market cap, or US$6.39m). Reported Earnings • Nov 17
Third quarter 2025 earnings released: EPS: LK₨0.11 (vs LK₨0.05 in 3Q 2024) Third quarter 2025 results: EPS: LK₨0.11 (up from LK₨0.05 in 3Q 2024). Revenue: LK₨78.0m (up 20% from 3Q 2024). Net income: LK₨13.0m (up 129% from 3Q 2024). Profit margin: 17% (up from 8.7% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. New Risk • Aug 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (LK₨264m revenue, or US$875k). Market cap is less than US$10m (LK₨2.16b market cap, or US$7.16m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to LK₨15.10, the stock trades at a trailing P/E ratio of 57.3x. Average trailing P/E is 33x in the Healthcare Services industry in Asia. Total returns to shareholders of 37% over the past three years. Reported Earnings • Aug 13
Second quarter 2025 earnings released: EPS: LK₨0.05 (vs LK₨0.04 in 2Q 2024) Second quarter 2025 results: EPS: LK₨0.05 (up from LK₨0.04 in 2Q 2024). Revenue: LK₨66.2m (up 11% from 2Q 2024). Net income: LK₨6.70m (up 22% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. New Risk • Jun 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (LK₨258m revenue, or US$858k). Market cap is less than US$10m (LK₨1.71b market cap, or US$5.69m). Minor Risk Share price has been volatile over the past 3 months (6.4% average weekly change). Annuncio • Jun 02
eChannelling PLC, Annual General Meeting, Jun 26, 2025 eChannelling PLC, Annual General Meeting, Jun 26, 2025, at 12:30 Sri Lanka Standard Time. Location: new wing hall, sri lanka foundation institute, no.100, sri lanka padanam mawatha, independence, square, colombo 07, colombo Sri Lanka Reported Earnings • May 09
First quarter 2025 earnings released: EPS: LK₨0.09 (vs LK₨0.09 in 1Q 2024) First quarter 2025 results: EPS: LK₨0.09 (in line with 1Q 2024). Revenue: LK₨66.9m (up 3.0% from 1Q 2024). Net income: LK₨11.4m (up 9.3% from 1Q 2024). Profit margin: 17% (up from 16% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Board Change • Apr 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non Executive Director T.M.Ruwanthi Perera was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 01
Full year 2024 earnings released: EPS: LK₨0.26 (vs LK₨0.36 in FY 2023) Full year 2024 results: EPS: LK₨0.26 (down from LK₨0.36 in FY 2023). Revenue: LK₨255.9m (down 5.6% from FY 2023). Net income: LK₨31.9m (down 27% from FY 2023). Profit margin: 13% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Annuncio • Feb 08
eChannelling PLC Appoints Suneth Haputhanthri as Independent, Non-Executive Director eChannelling PLC announced the appointment of Mr. Suneth Haputhanthri as independent, non-executive director. Effective date is 7 February 2025. Reported Earnings • Nov 15
Third quarter 2024 earnings released: EPS: LK₨0.05 (vs LK₨0.09 in 3Q 2023) Third quarter 2024 results: EPS: LK₨0.05 (down from LK₨0.09 in 3Q 2023). Revenue: LK₨65.1m (down 5.4% from 3Q 2023). Net income: LK₨5.69m (down 50% from 3Q 2023). Profit margin: 8.7% (down from 17% in 3Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to LK₨15.00, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 28x in the Healthcare Services industry in Asia. Total returns to shareholders of 76% over the past three years. Buy Or Sell Opportunity • Oct 14
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.0% to LK₨13.70. The fair value is estimated to be LK₨11.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 6.2%. Buy Or Sell Opportunity • Sep 26
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 3.7% to LK₨14.00. The fair value is estimated to be LK₨11.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 6.2%. Reported Earnings • Jul 30
Second quarter 2024 earnings released: EPS: LK₨0.04 (vs LK₨0.08 in 2Q 2023) Second quarter 2024 results: EPS: LK₨0.04 (down from LK₨0.08 in 2Q 2023). Revenue: LK₨59.8m (down 6.3% from 2Q 2023). Net income: LK₨5.49m (down 46% from 2Q 2023). Profit margin: 9.2% (down from 16% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Reported Earnings • May 17
First quarter 2024 earnings released: EPS: LK₨0.09 (vs LK₨0.082 in 1Q 2023) First quarter 2024 results: EPS: LK₨0.09 (up from LK₨0.082 in 1Q 2023). Revenue: LK₨65.0m (down 2.0% from 1Q 2023). Net income: LK₨10.4m (flat on 1Q 2023). Profit margin: 16% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings. Annuncio • Apr 21
eChannelling PLC, Annual General Meeting, May 14, 2024 eChannelling PLC, Annual General Meeting, May 14, 2024, at 12:30 Sri Lanka Standard Time. Location: "Ruby",Bandaranaike Memorial International Conference Hall (BMICH) Bauddhaloka Mawatha Colombo Sri Lanka Agenda: To consider the Statement of Accounts of the company for the year ended 31 December 2023; to consider election of directors; to consider reappointment of Messrs KPMG, Chartered Accountants as auditors and to determine their remuneration; to authorize the Directors to determine their remuneration; and to consider other business matters. Reported Earnings • Mar 03
Full year 2023 earnings released: EPS: LK₨0.36 (vs LK₨0.54 in FY 2022) Full year 2023 results: EPS: LK₨0.36 (down from LK₨0.54 in FY 2022). Revenue: LK₨271.2m (up 22% from FY 2022). Net income: LK₨43.8m (down 33% from FY 2022). Profit margin: 16% (down from 30% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 16
Third quarter 2023 earnings released: EPS: LK₨0.09 (vs LK₨0.13 in 3Q 2022) Third quarter 2023 results: EPS: LK₨0.09 (down from LK₨0.13 in 3Q 2022). Revenue: LK₨68.7m (up 43% from 3Q 2022). Net income: LK₨11.4m (down 27% from 3Q 2022). Profit margin: 17% (down from 33% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to LK₨16.50, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 123% over the past three years. Reported Earnings • Aug 05
Second quarter 2023 earnings released: EPS: LK₨0.08 (vs LK₨0.09 in 2Q 2022) Second quarter 2023 results: EPS: LK₨0.08 (down from LK₨0.09 in 2Q 2022). Revenue: LK₨63.9m (up 47% from 2Q 2022). Net income: LK₨10.2m (down 11% from 2Q 2022). Profit margin: 16% (down from 26% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to LK₨16.80, the stock trades at a trailing P/E ratio of 37x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 265% over the past three years. Reported Earnings • Apr 22
Full year 2022 earnings released: EPS: LK₨0.54 (vs LK₨0.44 in FY 2021) Full year 2022 results: EPS: LK₨0.54 (up from LK₨0.44 in FY 2021). Revenue: LK₨221.5m (up 15% from FY 2021). Net income: LK₨65.5m (up 23% from FY 2021). Profit margin: 30% (up from 28% in FY 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to LK₨18.80, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 43x in the Healthcare Services industry in Asia. Total returns to shareholders of 437% over the past three years. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to LK₨14.00, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 300% over the past three years. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Independent Non Executive Chairman Anthony Rohan Fernando was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 23% share price gain to LK₨13.80, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 151% over the past three years. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improved over the past week After last week's 17% share price gain to LK₨11.60, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 111% over the past three years. Reported Earnings • Nov 11
Third quarter 2022 earnings released: EPS: LK₨0.13 (vs LK₨0.13 in 3Q 2021) Third quarter 2022 results: EPS: LK₨0.13 (in line with 3Q 2021). Revenue: LK₨48.0m (up 2.5% from 3Q 2021). Net income: LK₨15.7m (down 4.0% from 3Q 2021). Profit margin: 33% (down from 35% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 24% share price gain to LK₨11.20, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 35x in the Healthcare Services industry in Asia. Total returns to shareholders of 115% over the past three years. Reported Earnings • Aug 09
Second quarter 2022 earnings released: EPS: LK₨0.09 (vs LK₨0.06 in 2Q 2021) Second quarter 2022 results: EPS: LK₨0.09 (up from LK₨0.06 in 2Q 2021). Revenue: LK₨43.4m (up 18% from 2Q 2021). Net income: LK₨11.4m (up 65% from 2Q 2021). Profit margin: 26% (up from 19% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 21% share price gain to LK₨8.70, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 43x in the Healthcare Services industry in Asia. Total returns to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improved over the past week After last week's 19% share price gain to LK₨6.90, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 47% over the past three years. Valuation Update With 7 Day Price Move • May 30
Investor sentiment deteriorated over the past week After last week's 19% share price decline to LK₨7.00, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 133% over the past three years. Reported Earnings • May 16
First quarter 2022 earnings released: EPS: LK₨0.16 (vs LK₨0.16 in 1Q 2021) First quarter 2022 results: EPS: LK₨0.16 (vs LK₨0.16 in 1Q 2021). Revenue: LK₨59.5m (up 17% from 1Q 2021). Net income: LK₨19.2m (down 1.5% from 1Q 2021). Profit margin: 32% (down from 38% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment deteriorated over the past week After last week's 27% share price decline to LK₨7.50, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 74% over the past three years. Buying Opportunity • Mar 29
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 71%. The fair value is estimated to be LK₨10.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% per annum over the last 3 years. Earnings per share has grown by 29% per annum over the last 3 years. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment deteriorated over the past week After last week's 18% share price decline to LK₨10.30, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 158% over the past three years. Reported Earnings • Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: LK₨0.44 (up from LK₨0.25 in FY 2020). Revenue: LK₨193.2m (up 49% from FY 2020). Net income: LK₨53.4m (up 78% from FY 2020). Profit margin: 28% (up from 23% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 22% share price decline to LK₨12.40, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 202% over the past three years. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment deteriorated over the past week After last week's 18% share price decline to LK₨17.10, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 42x in the Healthcare Services industry in Asia. Total returns to shareholders of 307% over the past three years. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to LK₨22.60, the stock trades at a trailing P/E ratio of 52.1x. Average trailing P/E is 49x in the Healthcare Services industry in Asia. Total returns to shareholders of 381% over the past three years. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 23% share price gain to LK₨21.30, the stock trades at a trailing P/E ratio of 49.1x. Average trailing P/E is 52x in the Healthcare Services industry in Asia. Total returns to shareholders of 384% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 15% share price gain to LK₨11.20, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 44x in the Healthcare Services industry in Asia. Total returns to shareholders of 149% over the past three years. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS LK₨0.13 (vs LK₨0.11 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: LK₨46.8m (up 17% from 3Q 2020). Net income: LK₨16.4m (up 19% from 3Q 2020). Profit margin: 35% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 24% share price gain to LK₨8.40, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 53x in the Healthcare Services industry in Asia. Total returns to shareholders of 79% over the past three years. Reported Earnings • Aug 12
Second quarter 2021 earnings released: EPS LK₨0.06 (vs LK₨0.02 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: LK₨36.7m (up 60% from 2Q 2020). Net income: LK₨6.90m (up 144% from 2Q 2020). Profit margin: 19% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improved over the past week After last week's 17% share price gain to LK₨7.00, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 55x in the Healthcare Services industry in Asia. Total returns to shareholders of 49% over the past three years. Reported Earnings • May 17
First quarter 2021 earnings released: EPS LK₨0.16 (vs LK₨0.03 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: LK₨50.8m (up 56% from 1Q 2020). Net income: LK₨19.5m (up LK₨16.4m from 1Q 2020). Profit margin: 38% (up from 9.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 25
New 90-day low: LK₨5.80 The company is down 15% from its price of LK₨6.80 on 27 November 2020. The Sri Lankan market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 7.0% over the same period. Reported Earnings • Feb 25
Full year 2020 earnings released: EPS LK₨0.25 (vs LK₨0.12 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: LK₨130.1m (flat on FY 2019). Net income: LK₨30.0m (up 100% from FY 2019). Profit margin: 23% (up from 12% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 02
New 90-day low: LK₨6.10 The company is down 14% from its price of LK₨7.10 on 04 November 2020. The Sri Lankan market is up 49% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 16% over the same period. Reported Earnings • Nov 04
Third quarter 2020 earnings released: EPS LK₨0.11 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: LK₨40.1m (up 26% from 3Q 2019). Net income: LK₨13.7m (up 244% from 3Q 2019). Profit margin: 34% (up from 13% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Sep 24
New 90-day high: LK₨6.00 The company is up 40% from its price of LK₨4.30 on 26 June 2020. The Sri Lankan market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 6.0% over the same period. 
